Corient Private Wealth LP Reduces Stake in Stryker Corporation $SYK

Key Points

• Corient Private Wealth reduced its Stryker stake by 9% in the second quarter, selling 98,797 shares and retaining 999,514 shares worth approximately $314.7 million. Institutional investors collectively own 77.09% of the company.
• Stryker reported quarterly EPS of $3.69, exceeding the $3.49 consensus estimate, while revenue rose 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, yielding about 1.3% annually.
• Shares recently traded near $269.98, well below their 52-week high of $392.55, although analysts maintain a “Moderate Buy” consensus with an average price target of $380.40. Insiders sold roughly $118.2 million of stock over the past 90 days, including a $100.8 million sale by director Ronda Stryker.

Corient Private Wealth LP reduced its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 9.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 999,514 shares of the medical technology company's stock after selling 98,797 shares during the period. Corient Private Wealth LP owned about 0.26% of Stryker worth $314,689,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Gables Capital Management Inc. bought a new position in Stryker during the second quarter valued at $25,000. Kilter Group LLC bought a new stake in shares of Stryker in the second quarter valued at $25,000. Highland Investment Advisors LLC purchased a new position in shares of Stryker during the 2nd quarter valued at $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the 4th quarter worth $26,000. Finally, Sankala Group LLC bought a new position in shares of Stryker during the 4th quarter worth $26,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Trading Down 2.0%

Shares of SYK stock opened at $269.98 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52-week low of $269.64 and a 52-week high of $392.55. The company has a market capitalization of $103.56 billion, a PE ratio of 27.98, a price-to-earnings-growth ratio of 1.72 and a beta of 0.76. The business's fifty day moving average is $325.65 and its 200 day moving average is $326.84.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts anticipate that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is 36.48%.

Analysts Set New Price Targets

A number of research firms recently weighed in on SYK. Raymond James Financial set a $370.00 price objective on shares of Stryker in a research note on Friday, July 31st. JPMorgan Chase & Co. decreased their price objective on Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Weiss Ratings restated a "hold (c)" rating on shares of Stryker in a research note on Friday, July 31st. BTIG Research decreased their price target on Stryker from $371.00 to $358.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. Finally, Leerink Partners lowered their price target on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a report on Friday, June 5th. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and an average target price of $380.40.

Insider Transactions at Stryker

In related news, Director Ronda Stryker sold 300,000 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker's principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.